Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection

Table 4 Univariable and multivariable logistic regression of factors associated with relapse

	Univariable			Multivariable
	OR	95%CI	P	OR	95%CI	P
Protease inhibitor, Telaprevir	0.41	0.15-1.10	0.08	-	-	-
Age, yr	1.00	0.96-1.05	0.95	-	-	-
Gender, female	1.36	0.53-3.48	0.52	-	-	-
Race, black	1.16	0.28-4.71	0.84	-	-	-
Diabetes	1.86	0.65-5.28	0.25	-	-	-
Depression	0.54	0.17-1.75	0.30	-	-	-
BMI, per kg/m2	0.98	0.88-1.10	0.76	-	-	-
IL28B, CC vs CT/TTa	-	-	-	-	-	-
Treatment history, naïve/relapser	1.10	0.45-2.72	0.84	-	-	-
HCV viral load, log IU/mL	1.74	0.80-3.78	0.16	-	-	-
Sub-genotype, 1a (vs all other)	6.26	1.75-22.45	0.01	5.15	1.40-18.97	0.01
Hemoglobin, g/dL	1.24	0.88-1.73	0.22	-	-	-
AFP, ng/mL	1.02	0.99-1.05	0.15	-	-	-
Albumin, g/dL	1.02	0.34-3.08	0.97	-	-	-
AST, U/L	1.01	1.00-1.02	0.06	-	-	-
ALT, U/L	1.00	0.99-1.01	0.23	-	-	-
Platelets, × 104/µL	0.95	0.89-1.02	0.19	-	-	-
Creatinine, mg/dL	1.41	0.72-2.74	0.31	-	-	-
Ferritin, ng/mL	1.00	0.99-1.01	0.26	-	-	-
eGFR, mL/min per 1.73 m2b	0.99	0.97-1.02	0.66	-	-	-
APRI score	1.16	0.94-1.43	0.17	-	-	-
FIB-4 score	1.03	0.94-1.13	0.49	-	-	-
APRI > 1.5	2.33	0.87-6.23	0.09	-	-	-
FiB-4 ≥ 3.25	2.77	1.12-6.86	0.03	2.77	1.07-7.22	0.04
Cirrhosis, transient elastography/biopsy	2.55	1.05-6.19	0.04	-	-	-

^aZero patients with IL28b CC genotype relapsed after completing treatment; ^bEstimated glomerular filtration rate calculated with epidemiology formula. BMI: Body mass index; HCV: Hepatitis C virus; AFP: Alpha-fetoprotein; AST: Aspartate transaminase; ALT: Alanine transaminase; eGFR: Estimated glomerular filtration rate; APRI: Aspartate transaminase to platelet ratio index.